Clinical Trial Update: Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations [Phase 2]

View source ↗

Summary

A Phase 2 study of Ulixertinib in patients with advanced solid tumors harboring MEK or atypical BRAF alterations was terminated, with results posted in June 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Ulixertinib (ulixertinib)

Snippet

Sponsor: BioMed Valley Discoveries, Inc | Conditions: Advanced Solid Tumor, BRAF Gene Mutation | Phase 2 | Status: TERMINATED | Results posted: 2024-06-04